299 related articles for article (PubMed ID: 30295079)
1. Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data.
Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
Integr Cancer Ther; 2018 Dec; 17(4):1115-1124. PubMed ID: 30295079
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma.
Maschio M; Zarabla A; Maialetti A; Marchesi F; Giannarelli D; Gumenyuk S; Pisani F; Renzi D; Galiè E; Mengarelli A
Integr Cancer Ther; 2019; 18():1534735419888584. PubMed ID: 31868025
[No Abstract] [Full Text] [Related]
3. Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.
Maschio M; Maialetti A; Marchesi F; Gumenyuk S; Pisani F; Papa E; Galiè E; Koudriavtseva T; Graziano G; Giannarelli D; Mengarelli A
Integr Cancer Ther; 2022; 21():15347354221114142. PubMed ID: 35866451
[TBL] [Abstract][Full Text] [Related]
4. Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Vidisheva AP; Wang J; Spektor TM; Bitran JD; Lutzky J; Tabbara IA; Ye JZ; Ailawadhi S; Stampleman LV; Steis RG; Moezi MM; Swift RA; Maluso TM; Udd KA; Eshaghian S; Nassir Y; Berenson JR
Support Care Cancer; 2017 Oct; 25(10):3217-3224. PubMed ID: 28455546
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
6. Acupuncture for Bortezomib-Induced Peripheral Neuropathy: Not Just for Pain.
Zhi WI; Ingram E; Li SQ; Chen P; Piulson L; Bao T
Integr Cancer Ther; 2018 Dec; 17(4):1079-1086. PubMed ID: 30027756
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Bortezomib-Induced Neuropathy Using Total Neuropathy Score (Reduced and Clinical Versions) and NCI CTCAE v4.0 in Newly Diagnosed Patients With Multiple Myeloma Receiving Bortezomib-Based Induction.
Lakshman A; Modi M; Prakash G; Malhotra P; Khadwal A; Jain S; Kumari S; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):513-519.e1. PubMed ID: 28842138
[TBL] [Abstract][Full Text] [Related]
8. Adhesive capsaicin 8% patch for improved control of pain caused by chemotherapy-induced peripheral neuropathy in patients with multiple myeloma: A single-centre, seven-case series.
Moreno-Alonso D; Llorens-Torromé S; Corcoy de Febrer B; Amandi García M; Serrano-Bermúdez G; Trelis-Navarro J; Mayoral-Rojals V; Serrano-Afonso A
J Oncol Pharm Pract; 2024 Jun; 30(4):752-758. PubMed ID: 38415287
[TBL] [Abstract][Full Text] [Related]
9. Blocking TRPA1 and TNF-α Signal Improves Bortezomib-Induced Neuropathic Pain.
Li C; Deng T; Shang Z; Wang D; Xiao Y
Cell Physiol Biochem; 2018; 51(5):2098-2110. PubMed ID: 30522101
[TBL] [Abstract][Full Text] [Related]
10. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
11. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
13. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy.
Yan W; Wu Z; Zhang Y; Hong D; Dong X; Liu L; Rao Y; Huang L; Zhang X; Wu J
Biomed Pharmacother; 2021 Oct; 142():112068. PubMed ID: 34463262
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib.
Peng L; Ye X; Zhou Y; Zhang J; Zhao Q
Support Care Cancer; 2015 Sep; 23(9):2813-24. PubMed ID: 25676487
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
Luczkowska K; Litwinska Z; Paczkowska E; Machalinski B
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29920472
[TBL] [Abstract][Full Text] [Related]
16. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.
Magrangeas F; Kuiper R; Avet-Loiseau H; Gouraud W; Guérin-Charbonnel C; Ferrer L; Aussem A; Elghazel H; Suhard J; Sakissian H; Attal M; C Munshi N; Sonneveld P; Dumontet C; Moreau P; van Duin M; Campion L; Minvielle S
Clin Cancer Res; 2016 Sep; 22(17):4350-4355. PubMed ID: 27060151
[TBL] [Abstract][Full Text] [Related]
17. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
[TBL] [Abstract][Full Text] [Related]
18. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
[No Abstract] [Full Text] [Related]
19. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score.
Zaroulis CK; Chairopoulos K; Sachanas SP; Maltezas D; Tzenou T; Pessach I; Koulieris E; Koutra E; Kilindireas K; Pangalis GA; Kyrtsonis MC
Leuk Lymphoma; 2014 Oct; 55(10):2277-83. PubMed ID: 24552516
[TBL] [Abstract][Full Text] [Related]
20. Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Sanchez L; Leleu X; Beaumont JL; Yu H; Hudgens S; Simonova M; Auner HW; Quach H; Delimpasi S; Špička I; Pour L; Kriachok I; Dimopoulos MA; Usenko G; Hájek R; Benjamin R; Sinha DK; Venner C; Illmer T; Garg MK; Stevens DA; Jagannath S; Levy M; Anderson LD; Bahlis NJ; Facon T; Cavo M; Chai Y; Ma X; Tang S; Leong H; Shah J; Shacham S; Kauffman M; Richardson P; Grosicki S
Am J Hematol; 2021 Oct; 96(10):E383-E386. PubMed ID: 34161627
[No Abstract] [Full Text] [Related]
[Next] [New Search]
